Search Bar & Filters
Found 677 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating 4D-150, an AAV-based gene therapy targeting VEGF-C and encoding aflibercept, in adults aged 50 and older with wet age-related macular degeneration AMD who are already receiving active anti-VEGF treatment. This Phase 12 trial includes dose escalation, randomized controlled masked expansion, and several substudies to assess safety, tolerability, and vector shedding. Participants will receive a single intravitreal injection of 4D-150 in the study eye. The trial includes Dose Escalation, Dose Expansion, Steroid Optimization, and Population Extension Cohorts. Some participants may also receive a one-time 4D-150 injection in the contralateral eye as part of a substudy. Aflibercept, a standard anti-VEGF drug, is given in a fixed regimen to control groups. Assessments occur monthly for 24 months, followed by a long-term follow-up up to 5 years to monitor safety and clinical activity. During the study, participants will have monthly evaluations including visual acuity tests using the ETDRS chart and retinal imaging by spectral domain optical coherence tomography SD-OCT. Researchers will track adverse events, need for additional aflibercept injections, and changes in retinal thickness and visual acuity. Safety and tolerability are monitored throughout the 52-week main period and during the extended follow-up. Some participants will also be involved in substudies focused on vector shedding and contralateral eye dosing, with regular safety assessments through week 52 and long-term monitoring through five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a study drug called LY4065967 for treating chronic low back pain CLBP. This trial is part of a larger master protocol aimed at speeding up the development of new treatments for chronic pain conditions. The study focuses on adults with a history of low back pain lasting at least three months. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study uses a double-blind design, meaning neither the participants nor the researchers know who receives the study drug or placebo. The treatment phase lasts for 8 weeks, during which participants take the assigned medication regularly. During the study, participants will be assessed at the start and at week 8 for changes in pain intensity using a numeric rating scale. Other evaluations include overall improvement, worst pain intensity, sleep quality, emotional functioning, use of rescue medication, and disability related to back pain. The trial includes safety monitoring and will continue until April 2027, with visits scheduled to track these outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating diabetic peripheral neuropathic pain DPNP. This study is part of a larger chronic pain master protocol aimed at speeding up the development of new treatments for chronic pain conditions. Participants have diabetes and suffer from symmetrical nerve pain in their lower limbs. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study is double-blinded, meaning neither participants nor researchers know who receives which treatment. The treatment phase will last 8 weeks, during which pain and related symptoms will be monitored and compared between the groups. During the study, participants will have their pain intensity measured using a numeric rating scale at the start and at week 8. Other assessments include pain interference, overall improvement, sleep quality, emotional functioning, and daily use of rescue medication. The study involves regular monitoring to evaluate these outcomes and ensure participant safety throughout the 8-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating knee pain caused by osteoarthritis. This study is part of a larger effort called the chronic pain master protocol to speed up the development of new treatments for chronic pain conditions. The trial is a randomized, placebo-controlled Phase 2 study focusing on adults with knee osteoarthritis pain lasting more than 12 weeks. Participants will be randomly assigned to receive either LY4065967 or a placebo, both administered orally. The study compares these two groups to assess how well LY4065967 works in reducing knee pain and improving related symptoms. Treatment effects will be measured over an 8-week period, with evaluations at the start and end of this timeframe. During the study, participants will undergo regular assessments including pain intensity ratings using the Numeric Rating Scale, evaluations of arthritis symptoms, sleep quality, emotional functioning, and use of any rescue medication. Researchers will monitor the safety and effectiveness of the treatment through these measures. The total study duration for participants is approximately 8 weeks, with monitoring at baseline and week 8 to observe changes from the start of treatment.
Actively Recruiting
Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.
Actively Recruiting
Researchers are exploring new treatments for high-risk non-muscle invasive bladder cancer HR NMIBC, a type of cancer that affects the bladder lining without spreading to the bladder muscle or beyond. This research focuses on the safety and tolerability of MK-3120, a study drug, following the standard tumor removal procedure called transurethral resection of the bladder tumor TURBT. The study is a Phase 12 clinical trial investigating MK-3120 in people with HR NMIBC who are either Bacillus Calmette-Gurin BCG-nave or BCG-exposed. Participants will receive MK-3120 through intravesical administration, meaning the drug is delivered directly into the bladder. The treatment schedule begins with once-weekly doses for the first 6 weeks, followed by once-monthly doses for 9 months. This dosing plan aims to evaluate the drugs safety and effects over a period that includes the initial intensive phase and a maintenance phase. During the study, participants will be monitored closely for dose-limiting toxicities and adverse events up to about 24 months. Researchers will assess if participants discontinue treatment due to side effects within roughly 12 months. The main goal is to evaluate the safety profile of MK-3120 and observe its complete response rate up to approximately 3 months. Participants can expect regular assessments, including safety monitoring and treatment visits, throughout their involvement in the trial lasting several months to years.
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the FloStent, a medical device used for treating men experiencing symptoms of Benign Prostatic Hyperplasia BPH. The study compares the FloStent implant procedure to a sham procedure without deploying the device. It involves men aged 45 and older with symptomatic BPH to better understand how this device may impact urinary symptoms. Participants will undergo a flexible cystoscopy procedure. Those randomized to the treatment group will receive the FloStent implant during this procedure, while those in the control group will have the cystoscopy without the implant deployment, serving as a sham treatment. The study is randomized, double-blind, and includes parallel groups to compare outcomes over time. Throughout the study, participants will be assessed on changes in their International Prostate Symptom Score IPSS over 12 months. Researchers will monitor symptom improvements at 3, 6, and 12 months to evaluate response rates. Participants will complete study visits and follow the protocol to help researchers gather data on the devices safety and impact on urinary symptoms.
Actively Recruiting
Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
1-10 of 677
1